Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2007

Open Access 01-12-2007 | Research

Exceptionally high incidence of symptomatic grade 2–5 radiation pneumonitis after stereotactic radiation therapy for lung tumors

Authors: Hideomi Yamashita, Keiichi Nakagawa, Naoki Nakamura, Hiroki Koyanagi, Masao Tago, Hiroshi Igaki, Kenshiro Shiraishi, Nakashi Sasano, Kuni Ohtomo

Published in: Radiation Oncology | Issue 1/2007

Login to get access

Abstract

Background

To determine the usefulness of dose volume histogram (DVH) factors for predicting the occurrence of radiation pneumonitis (RP) after application of stereotactic radiation therapy (SRT) for lung tumors, DVH factors were measured before irradiation.

Methods

From May 2004 to April 2006, 25 patients were treated with SRT at the University of Tokyo Hospital. Eighteen patients had primary lung cancer and seven had metastatic lung cancer. SRT was given in 6–7 fields with an isocenter dose of 48 Gy in four fractions over 5–8 days by linear accelerator.

Results

Seven of the 25 patients suffered from RP of symptomatic grade 2–5 according to the NCI-CTC version 3.0. The overall incidence rate of RP grade2 or more was 29% at 18 months after completing SRT and three patients died from RP. RP occurred at significantly increased frequencies in patients with higher conformity index (CI) (p = 0.0394). Mean lung dose (MLD) showed a significant correlation with V5–V20 (irradiated lung volume) (p < 0.001) but showed no correlation with CI. RP did not statistically correlate with MLD. MLD had the strongest correlation with V5.

Conclusion

Even in SRT, when large volumes of lung parenchyma are irradiated to such high doses as the minimum dose within planning target volume, the incidence of lung toxicity can become high.
Appendix
Available only for authorised users
Literature
1.
Nagata Y, Negoro Y, Aoki T, Mizowaki T, Takayama K, Kokubo M, Araki N, Mitsumori M, Sasai K, Shibamoto Y, Koga S, Yano S, Hiraoka M: Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2002, 52: 1041-1046. 10.1016/S0360-3016(01)02731-6CrossRef
2.
Uematsu M, Shioda A, Tahara K, Fukui T, Yamamoto F, Tsumatori G, Ozeki Y, Aoki T, Watanabe M, Kusano S: Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients a preliminary experience. Cancer 1998, 82: 1062-1070. 10.1002/(SICI)1097-0142(19980315)82:6<1062::AID-CNCR8>3.0.CO;2-GCrossRef
3.
Nakagawa K, Aoki Y, Tago M, Terahara A, Ohtomo K: Megavoltage CT-assisted stereotactic radiosurgery for thoracic tumors original research in the treatment of thoracic neoplasms. Int J Radiat Oncol Biol Phys 2000, 48: 449-457. 10.1016/S0360-3016(00)00617-9CrossRef
4.
Wulf J, Hadinger U, Oppitz U, Thiele W, Ness-Dourdoumas R, Flentje M: Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol 2001, 177: 645-655. 10.1007/PL00002379CrossRef
5.
Hara R, Itami J, Kondo T, Aruga T, Abe Y, Ito M, Fuse M, Shinohara D, Nagaoka T, Kobiki T: Stereotactic single high dose irradiation of lung tumors under respiratory gating. Radiother Oncol 2002, 63: 159-163. 10.1016/S0167-8140(02)00063-4CrossRef
6.
Onimaru R, Shirato H, Shimizu S, Kitamura K, Xu B, Fukumoto S, Chang TC, Fujita K, Oita M, Miyasaka K, Nishimura M, Dosaka-Akita H: Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys 2003, 56: 126-135. 10.1016/S0360-3016(03)00095-6CrossRef
7.
Hof H, Herfarth KK, Munter M, Hoess A, Motsch J, Wannenmacher M, Debus JJ: Stereotactic single-dose radiotherapy of stage I non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2003, 56: 335-341. 10.1016/S0360-3016(02)04504-2CrossRef
8.
Whyte RI, Crownover R, Murphy MJ, Martin DP, Rice TW, DeCamp MM Jr, Rodebaugh R, Weinhous MS, Le QT: Stereotactic radiosurgery for lung tumors preliminary report of a phase I trial. Ann Thorac Surg 2003, 75: 1097-1101. 10.1016/S0003-4975(02)04681-7CrossRef
9.
Takai Y, Mituya M, Nemoto K, Ogawa Y, Kakuto Y, Matusita H, Takeda K, Takahashi C, Yamada S: [Simple method of stereotactic radiotherapy without stereotactic body frame for extracranial tumors]. Nippon Igaku Hoshasen Gakkai Zasshi 2001, 61: 403-407.PubMed
10.
Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J: Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24: 4833-4839. 10.1200/JCO.2006.07.5937CrossRef
11.
Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, Perez CA: Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999, 45: 323-329. 10.1016/S0360-3016(99)00183-2CrossRef
12.
Matsuo Y, Takayama K, Nagata Y, Kunieda E, Tateoka K, Ishizuka N, Mizowaki T, Norihisa Y, Sakamoto M, Narita Y, Ishikura S, Hiraoka M: Interinstitutional variations in planning for stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys 2007, 68: 416-425.CrossRef
13.
Lagerwaard FJ, Van Sornsen de Koste JR, Nijssen-Visser MR, Schuchhard-Schipper RH, Oei SS, Munne A, Senan S: Multiple "slow" CT scans for incorporating lung tumor mobility in radiotherapy planning. Int J Radiat Oncol Biol Phys 2001, 51: 932-937. 10.1016/S0360-3016(01)01716-3CrossRef
14.
van Sornsen de Koste JR, Lagerwaard FJ, Schuchhard-Schipper RH, Nijssen-Visser MR, Voet PW, Oei SS, Senan S: Dosimetric consequences of tumor mobility in radiotherapy of stage I non-small cell lung cancer--an analysis of data generated using 'slow' CT scans. Radiother Oncol 2001, 61: 93-99. 10.1016/S0167-8140(01)00373-5CrossRef
15.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92: 205-216. 10.1093/jnci/92.3.205CrossRef
16.
Knoos T, Kristensen I, Nilsson P: Volumetric and dosimetric evaluation of radiation treatment plans: radiation conformity index. Int J Radiat Oncol Biol Phys 1998, 42: 1169-1176. 10.1016/S0360-3016(98)00239-9CrossRef
17.
Hara R, Itami J, Komiyama T, Katoh D, Kondo T: Serum levels of KL-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung tumors. Chest 2004, 125: 340-344. 10.1378/chest.125.1.340CrossRef
18.
Takayama K, Nagata Y, Negoro Y, Mizowaki T, Sakamoto T, Sakamoto M, Aoki T, Yano S, Koga S, Hiraoka M: Treatment planning of stereotactic radiotherapy for solitary lung tumor. Int J Radiat Oncol Biol Phys 2005, 61: 1565-1571. 10.1016/j.ijrobp.2004.12.066CrossRef
19.
Song DY, Benedict SH, Cardinale RM, Chung TD, Chang MG, Schmidt-Ullrich RK: Stereotactic body radiation therapy of lung tumors: preliminary experience using normal tissue complication probability-based dose limits. Am J Clin Oncol 2005, 28: 591-596. 10.1097/01.coc.0000182428.56184.afCrossRef
20.
Onishi H, Nagata Y, Shirato H, Gomi K, Karasawa K, Arimoto T, Hayakawa K, Takai Y, Kimura T, Takeda A: Stereotactic hypofractionated high-dose irradiation for stage I non-small cell lung carcinoma: Clinical outcomes in 273 cases of a Japanese multi-institutional study. ASCO 2004.,22(14S): (July 15 Supplement) abstract No: 7003
21.
Wulf J, Haedinger U, Oppitz U, Thiele W, Mueller G, Flentje M: Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys 2004, 60: 186-196. 10.1016/j.ijrobp.2004.02.060CrossRef
22.
Anonymous: Prescribing, recording and reporting photon beam therapy (supplement to ICRU Report 50). In Report 62, International Commission on Radiation Units and Measurements. Washington, DC; 1999.
23.
Shaw E, Kline R, Gillin M, Souhami L, Hirschfeld A, Dinapoli R, Martin L: Radiation Therapy Oncology Group: Radiosurgery quality assurance guidelines. Int J Radiat Oncol Biol Phys 1993, 27: 1231-1239.CrossRef
24.
Feuvret L, Noel G, Mazeron JJ, Bey P: Conformity index: a review. Int J Radiat Oncol Biol Phys 2006, 64: 333-342. 10.1016/j.ijrobp.2005.09.028CrossRef
25.
Paddick I: A simple scoring ratio to index the conformity of radiosurgical treatment plans. Technical note. J Neurosurg 2000,93(Suppl 3):219-222.CrossRef
26.
Takayama K, Nagata Y, Negoro Y, Mizowaki T, Sakamoto T, Sakamoto M, Aoki T, Yano S, Koga S, Hiraoka M: Treatment planning of stereotactic radiotherapy for solitary lung tumor. Int J Radiat Oncol Biol Phys 2005, 61: 1565-1571. 10.1016/j.ijrobp.2004.12.066CrossRef
27.
Armstrong J, McGibney C: The impact of three-dimensional radiation on the treatment of non-small cell lung cancer. Radiother Oncol 2000, 56: 157-167. 10.1016/S0167-8140(00)00207-3CrossRef
28.
Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, Yarnold J, Horwich A: Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: A randomised trial. Lancet 1999, 353: 267-272. 10.1016/S0140-6736(98)05180-0CrossRef
29.
Lee WR, Hanks GE, Hanlon AL, Schultheiss TE, Hunt MA: Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a significant dose effect. Int J Radiat Oncol Biol Phys 1996, 35: 251-257. 10.1016/0360-3016(96)00064-8CrossRef
30.
Yorke ED, Jackson A, Rosenzweig KE, Merrick SA, Gabrys D, Venkatraman ES, Burman CM, Leibel SA, Ling CC: Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2002, 54: 329-339. 10.1016/S0360-3016(02)02929-2CrossRef
31.
Hernando ML, Marks LB, Bentel GC, Zhou SM, Hollis D, Das SK, Fan M, Munley MT, Shafman TD, Anscher MS, Lind PA: Radiation induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 2001, 51: 650-659. 10.1016/S0360-3016(01)01685-6CrossRef
32.
Paludan M, Traberg Hansen A, Petersen J, Grau C, Hoyer M: Aggravation of dyspnea in stage I non-small cell lung cancer patients following stereotactic body radiotherapy: Is there a dose-volume dependency? Acta Oncol 2006, 45: 818-822. 10.1080/02841860600915314CrossRef
33.
Kohno N, Hamada H, Fujioka S, Hiwada K, Yamakido M, Akiyama M: Circulating Antigen KL-6 and Lactate Dehydorogenase for Monitoring Irradiated Patients with Lung Cancer. Chest 1992, 102: 117-122.CrossRef
34.
Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M: New serum indicator of interstitial pneumonitis activity: sialylated carbohydrate antigen KL-6. Chest 1989, 96: 68-73.CrossRef
35.
Goto K, Kodama T, Sekine I, Kakinuma R, Kubota K, Hojo F, Matsumoto T, Ohmatsu H, Ikeda H, Ando M, Nishiwaki Y: Serum levels of KL-6 are useful biomarkers for severe radiation pneumonitis. Lung Cancer 2001, 34: 141-148. 10.1016/S0169-5002(01)00215-XCrossRef
36.
Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M: New serum indicator of interstitial pneumonitis activity: sialylated carbohydrate antigen KL-6. Chest 1989, 96: 68-73.CrossRef
37.
Wara WM, Phillips TL, Margolis LW, Smith V: Radiation pneumonitis: A new approach to the derivation of time-dose factors. Cancer 1973, 32: 547-552. CrossRef
38.
Fritz P, Kraus HJ, Muhlnickel W, Hammer U, Dolken W, Engel-Riedel W, Chemaissani A, Stoelben E: Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases. Radiat Oncol 2006, 1: 30. 10.1186/1748-717X-1-30CrossRef
39.
Belderbos JS, De Jaeger K, Heemsbergen WD, Seppenwoolde Y, Baas P, Boersma LJ, Lebesque JV: First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol 2003, 66: 119-126. 10.1016/S0167-8140(02)00377-8CrossRef
40.
Hope AJ, Lindsay PE, El Naqa I, Alaly JR, Vicic M, Bradley JD, Deasy JO: Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. Int J Radiat Oncol Biol Phys 2006, 65: 112-124. 10.1016/j.ijrobp.2005.11.046CrossRef
Metadata
Title
Exceptionally high incidence of symptomatic grade 2–5 radiation pneumonitis after stereotactic radiation therapy for lung tumors
Authors
Hideomi Yamashita
Keiichi Nakagawa
Naoki Nakamura
Hiroki Koyanagi
Masao Tago
Hiroshi Igaki
Kenshiro Shiraishi
Nakashi Sasano
Kuni Ohtomo
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2007
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-2-21

Other articles of this Issue 1/2007

Radiation Oncology 1/2007 Go to the issue

Research

Verifying 4D gated radiotherapy using time-integrated electronic portal imaging: a phantom and clinical study

Research

Experimental iodine-125 seed irradiation of intracerebral brain tumors in nude mice

Research

A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk

Research

IMRT in oral cavity cancer

Research

Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans

Review

The role of PDGF in radiation oncology